A Phase 1, 7 Day Repeat Dose, Parallel-Group, Open-Label Study to Evaluate the Safety and Pharmacokinetics of Intravenous Infusion of MTP-131 Administered in Subjects With Impaired Renal Function
Phase of Trial: Phase I
Latest Information Update: 23 Nov 2015
At a glance
- Drugs Elamipretide (Primary)
- Indications Renal impairment
- Focus Pharmacokinetics
- Sponsors Stealth BioTherapeutics
- 17 Nov 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 May 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
- 07 May 2015 New trial record